Keenova seeks Xiaflex expansion on late-stage rare disease win
Keenova Therapeutics is hoping to step into a new market with Xiaflex (collagenase clostridium histolyticum), after the drug netted a Phase III win in rare foot disease, plantar fibromatosis. To put Xiaflex to the test in this indication, Keenova conducted …